Skip to main content
Psychedex

6Node page

what any key link opens

psx:substance/oxycodone/section/summary.full@1

sectionreferenced by edges — no row of its own

derived from · upstream

feeds · downstream

none recorded

Closure of psx:substance/oxycodone/section/summary.full@1: 86 upstream, 103 downstream.

psx:substance/oxycodone/section/summary.full@1
├─ informed_by  claim/3278dee2-8bb3-423e-b3f9-3a27fdea806e  Claim in summary — inconclusive  working
├─ informed_by  claim/7edd52e0-bd3c-4e16-9d2f-c86c91a4240f  Claim in summary — inconclusive  working
├─ informed_by  claim/e1e3c546-5bd2-4d37-8d0a-29dde0a8267f  Claim in summary — inconclusive  working
├─ informed_by  claim/103ff124-0e67-41b7-b559-163f74286e85  Claim in summary — inconclusive  working
├─ informed_by  claim/9800d9e7-bd2d-4e03-bbfa-100395f65b55  Claim in summary — inconclusive  working
├─ informed_by  claim/552ee8a7-807c-4f4c-940b-8cc84c70e0cc  Claim in summary — inconclusive  working
├─ informed_by  claim/668b0ef6-7dbc-49ff-8d37-39fff8c23f9a  Claim in summary — inconclusive  working
├─ informed_by  claim/b44bda38-6248-4f16-8c08-21dc65df8a45  Claim in summary — inconclusive  working
├─ informed_by  claim/2d69676f-7a53-49cd-96d9-45a9e673ebe0  Claim in summary — inconclusive  working
├─ informed_by  claim/6e70858e-dbd8-48bd-99e4-0050cd119099  Claim in summary — inconclusive  working
├─ informed_by  claim/4e7786e8-2f5e-45c6-be2b-cf7f9c1ad69b  Claim in summary — inconclusive  working
├─ informed_by  claim/bf1e4ee2-6fbe-4cc2-862e-f5e268255677  Claim in summary — inconclusive  working
├─ informed_by  claim/5a4ccfd4-9997-44a1-ae0c-b1497bc592b1  Claim in summary — inconclusive  working
├─ informed_by  claim/08396b77-6d05-493e-8014-c82082644a11  Claim in summary — inconclusive  working
├─ informed_by  claim/940cdb60-6acf-49e9-b921-8d64e584f02d  Claim in summary — inconclusive  working
├─ informed_by  claim/19bf5e70-b348-4ee2-9630-4f15e753a715  Claim in summary — inconclusive  working
├─ informed_by  claim/bd64c37d-9465-4ea9-94fa-97aa08de4fdb  Claim in summary — inconclusive  working
├─ informed_by  claim/124cabd9-2a00-4ca7-bf82-1131cd8859a8  Claim in summary — inconclusive  working
├─ informed_by  claim/0963b942-59d1-4558-8b16-5010ae1c0523  Claim in summary — inconclusive  working
├─ informed_by  claim/6f5ac45d-0925-4539-adef-7808bc08b4be  Claim in summary — inconclusive  working
├─ informed_by  claim/26bd6faa-9407-4903-bfd3-fd44ab7a41fd  Claim in summary — inconclusive  working
├─ informed_by  claim/083985cf-83d1-4431-9518-b168137baab8  Claim in summary — inconclusive  working
├─ informed_by  claim/e03f8acf-ddab-46b4-b336-be5ce52f50f4  Claim in summary — inconclusive  working
├─ informed_by  claim/c55a7054-761e-42bf-bcb0-7a8485b5ca5c  Claim in summary — inconclusive  working
├─ informed_by  claim/18d5a384-4d5b-4f1c-a315-75e5966440da  Claim in summary — inconclusive  working
├─ informed_by  claim/fa924f21-da9e-4943-b07f-8d62aa904c13  Claim in summary — inconclusive  working
├─ informed_by  claim/cecc7927-2943-4986-ae12-6131048dbf38  Claim in summary — inconclusive  working
├─ informed_by  claim/499d9f11-2156-48b5-b385-9338f7c0031a  Claim in summary — inconclusive  working
├─ informed_by  claim/a85489fa-0ecc-4e06-933d-8907db39aafa  Claim in summary — inconclusive  working
├─ informed_by  claim/f981d907-f422-4a8a-8ed5-0a93505c38d2  Claim in summary — inconclusive  working
  ├─ used  src/pmid:12669998  Oxycodone involvement in drug abuse deaths: a DAWN-based classification scheme applied to an oxycodone postmortem database containing over 1000 cases
  ├─ used  src/pmid:17525040  Oxycodone: a pharmacological and clinical review
  ├─ used  src/doi:10.1007/s40262-018-00731-3  Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone
  ├─ used  src/doi:10.1146/annurev-publhealth-031914-122957  The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of Addiction
  ├─ used  src/doi:10.1371/journal.pone.0184876  Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse
  ├─ used  src/pmid:31855381  Mu Receptors (StatPearls/NCBI)
  ├─ used  src/doi:10.1016/j.pain.2007.03.022  Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain
  ├─ used  src/doi:10.1371/journal.pone.0217371  Comprehensive molecular pharmacology screening reveals potential new receptor interactions for clinically relevant opioids
  ├─ used  src/doi:10.1016/j.sjpain.2009.09.003  Does co-administration of paroxetine change oxycodone analgesia
  ├─ used  src/doi:10.1007/s12325-021-01766-y  Management of Opioid-Induced Constipation and Bowel Dysfunction
  ├─ used  src/doi:10.1111/j.1533-2500.2008.00204.x  Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel
  ├─ used  src/doi:10.1073/pnas.1000751107  Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling
  ├─ used  src/doi:10.1016/j.neuropharm.2021.108925  A limited access oral oxycodone paradigm produces physical dependence and mesocorticolimbic region-dependent increases in DeltaFosB expression without preference
      ├─ used  src/url:e866fccbb6332ecd  Oxycodone pharmacology overview (StatPearls/NCBI Bookshelf)
      ├─ used  src/url:6424421adc42a45d  Oxycodone synthesis history (Freund & Speyer, 1916)
      ├─ used  src/doi:10.3390/neurolint13040059  Prescription of Controlled Substances: Benefits and Risks
      ├─ used  src/doi:10.15585/mmwr.mm675152e1  Drug and Opioid-Involved Overdose Deaths - United States, 2013-2017
      ├─ used  src/doi:10.1080/03007995.2023.2178080  Evaluating the effectiveness of reformulated extended-release oxycodone with abuse-deterrent properties on reducing non-oral abuse
      ├─ used  src/doi:10.1016/j.addbeh.2019.106268  The impact of the abuse-deterrent reformulation of extended-release OxyContin on prescription pain reliever misuse and heroin initiation
      ├─ used  src/doi:10.1002/pds.70066  Oxymorphone and Oxycodone Pharmacy Purchases in US Counties: Prelude to the Largest Rural HIV Outbreak in US History
      ├─ used  src/doi:10.1038/s41397-021-00253-5  Impact of genetic variation in CYP2C19, CYP2D6, and CYP3A4 on oxycodone and its metabolites in a large database of clinical urine drug tests
      ├─ used  src/doi:10.1177/02692163251362563  Oxycodone/naloxone PR versus oxycodone PR in advanced cancer (ENhANCE trial)
      ├─ used  src/doi:10.15585/mmwr.rr6501e1  CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016.
      ├─ used  src/doi:10.15585/mmwr.rr7103a1  CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022
      ├─ used  src/url:48f93c34f9e039f6  Oxycodone physicochemical properties (CAS 76-42-6)
      ├─ used  src/pmid:15301633  Discriminative stimulus, reinforcing, physical dependence, and antinociceptive effects of oxycodone in mice, rats, and rhesus monkeys
      ├─ used  src/doi:10.1016/j.neulet.2017.02.002  Characterization of [3H] oxymorphone binding sites in mouse brain: Quantitative autoradiography in opioid receptor knockout mice
      ├─ used  src/doi:10.1016/j.jpba.2016.09.024  Characterization of oxycodone in vitro metabolism by human cytochromes P450 and UDP-glucuronosyltransferases
      ├─ used  src/doi:10.1080/14622416.2024.2430161  Do CYP2D6 genotypes affect oxycodone dose, pharmacokinetics, pain, and adverse effects in cancer?
      ├─ used  src/doi:10.1002/bdd.2215  Physiologically based pharmacokinetic modelling of oxycodone drug-drug interactions
      ├─ used  src/doi:10.1093/jat/bkv030  Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolism
      ├─ used  src/doi:10.1093/jat/bkt060  In vitro inhibition of methadone and oxycodone cytochrome P450-dependent metabolism: reversible inhibition by H2-receptor agonists and proton-pump inhibitors
      ├─ used  src/doi:10.1007/s40262-023-01255-1  Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer
      ├─ used  src/pmid:9062618  Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone
      ├─ used  src/doi:10.1054/bjoc.2001.1680  Morphine and alternative opioids in cancer pain: the EAPC recommendations
      ├─ used  src/doi:10.1056/nejmsa1406143  Trends in Opioid Analgesic Abuse and Mortality in the United States
      ├─ used  src/doi:10.1016/j.pbb.2021.173241  Minocycline attenuates oxycodone-induced positive subjective responses in non-dependent, recreational opioid users
      ├─ used  src/doi:10.1016/j.pbb.2025.173968  Cannabidiol interactions with oxycodone analgesia in an operant orofacial cutaneous thermal pain assay
      ├─ used  src/doi:10.3390/jcm14051410  Comprehensive Analysis of Strong Opioid Side Effects in Palliative Care Using the SIDER Database
      ├─ used  src/doi:10.1038/s41386-018-0284-5  Dopamine D3R antagonist VK4-116 attenuates oxycodone self-administration and reinstatement
      ├─ used  src/pmid:26086633  Opioid Overdose Prevention Programs Providing Naloxone to Laypersons - United States, 2014
      ├─ used  src/doi:10.1001/jamanetworkopen.2022.28588  Characteristics of Prescription Opioid Analgesics in Pregnancy and Risk of Neonatal Opioid Withdrawal Syndrome in Newborns
      ├─ used  src/doi:10.1007/s00213-022-06257-8  Perinatal oxycodone exposure causes long-term sex-dependent changes in weight trajectory and sensory processing in adult mice
      ├─ used  src/doi:10.1097/01.j.pain.0000460357.01998.f1  Rates of opioid misuse, abuse, and addiction in chronic pain
      ├─ used  src/doi:10.1056/nejmra1508490  Relationship between Nonmedical Prescription-Opioid Use and Heroin Use
      ├─ used  src/doi:10.1016/j.ejphar.2021.174111  Validation and characterization of oxycodone physical dependence in C57BL/6J mice
      ├─ used  src/doi:10.1097/FBP.0000000000000780
      ├─ used  src/doi:10.1111/cts.12737  Once-Daily Oxycodone Prolonged-Release Tablets Are Resistant to Alcohol-Induced Dose Dumping
      ├─ used  src/doi:10.1016/j.drugalcdep.2012.01.023  Separate and combined psychopharmacological effects of alprazolam and oxycodone in healthy volunteers
      ├─ used  src/doi:10.1021/acschemneuro.0c00810  Drug-Drug Interaction Between Oxycodone and Diazepam by a Combined in Silico Pharmacokinetic and Pharmacodynamic Modeling Approach
      ├─ used  src/doi:10.1371/journal.pmed.1002396  Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study
      ├─ used  src/doi:10.1111/add.13843  Risk to heroin users of polydrug use of pregabalin or gabapentin
      ├─ used  src/doi:10.1007/s00204-018-2244-6  Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects
      ├─ used  src/doi:10.7759/cureus.57403  Altered Mental Status in an Octogenarian: Serotonin Syndrome from Venlafaxine and Oxycodone
      ├─ derived_from  gen/d26cdcd5-28b0-4261-95c6-7e28dfce29ae  Generation — pipeline-v5
      └─ generated_by  pub/a005318f-e6a8-46bc-bbca-9518d4baf5a3  Publication — backfill
    ├─ used  version/1  Revision 1
    ├─ used  claim/fea28351-015a-41f2-a3c5-9836b9f3528f  Claim in safety — inconclusive  working
    ├─ used  claim/11c17122-a9cc-49ec-89c0-75c9a24503eb  Claim in safety — inconclusive  working
    ├─ used  claim/b52d6e38-4724-4a1e-935a-12f8bf52b972  Claim in safety — inconclusive  working
    ├─ used  claim/488924db-42be-4b03-94fc-e5d6224cbece  Claim in safety — inconclusive  working
    ├─ used  claim/dad12d56-9383-4d40-9479-cc00c0b4ee39  Claim in safety — inconclusive  working
    ├─ used  claim/7ce88abf-cc22-4b44-a94c-662018934ed1  Claim in safety — inconclusive  working
    ├─ used  claim/19d62f91-1621-4fb9-baf0-76c9d7c10532  Claim in safety — inconclusive  working
    ├─ used  claim/d188824a-22f1-40fd-9ed9-fd40b6581fcb  Claim in safety — inconclusive  working
    ├─ used  claim/134e3d2f-4716-41a8-81b0-8320974971c9  Claim in effects-overview — inconclusive  working
    ├─ used  claim/b760a324-6123-41fb-accc-23cf55d774fb  Claim in pharmacology — inconclusive  working
    ├─ used  claim/bc94db45-18d9-4c0b-bc41-e5b7af509d5d  Claim in pharmacology — inconclusive  working
    ├─ used  claim/25380fdf-a420-4e66-9faf-5b938d42bac8  Claim in pharmacology — inconclusive  working
    ├─ used  claim/2e3b458e-9763-4e32-ac64-989196889dbf  Claim in pharmacology — inconclusive  working
    ├─ used  claim/476d3b6c-497c-4fa5-aa24-003c68242346  Claim in safety — inconclusive  working
    ├─ used  claim/8409c863-fdc2-416b-b931-8d050378d7ac  Claim in chemistry — inconclusive  working
    ├─ used  claim/e22dc362-1473-49d4-9528-890d0302fd78  Claim in pharmacokinetic-detail — inconclusive  working
    ├─ used  claim/4bdd4b56-919c-4343-b9b7-9a61d3efa81f  Claim in pharmacokinetic-detail — inconclusive  working
    ├─ used  claim/1c01d391-97c7-4f22-a1f8-98eaeb0c9727  Claim in comparative-pharmacology — inconclusive  working
    ├─ used  claim/b39ed47c-99b2-4631-9163-376f1b1942ae  Claim in safety — inconclusive  working
    ├─ used  claim/f5ab5be2-7baf-438f-bdc9-146e309b018e  Claim in pharmacology — inconclusive  working
    ├─ used  claim/dd6443ce-c75c-40d0-92be-b2e213e9e110  Claim in pharmacology — inconclusive  working
    ├─ used  claim/a8167b1c-6ee0-4e8d-b512-f04a5240a37d  Claim in pharmacology — inconclusive  working
    ├─ used  claim/62ea7a01-7031-4a11-9bea-1361967bc3b2  Claim in pharmacology — inconclusive  working
    ├─ used  claim/3387dfd4-6f09-44ed-9b49-2923a6a1f77f  Claim in chemistry — inconclusive  working
    ├─ used  claim/a3dd8939-30bd-4227-b2b9-91aed1128cd2  Claim in pharmacokinetic-detail — inconclusive  working
    ├─ used  claim/20d6d496-9718-4c1d-9da7-1c4df43ecef1  Claim in pharmacokinetic-detail — inconclusive  working
    ├─ used  claim/60e962f1-3a4e-4e22-bb01-9b782caab641  Claim in comparative-pharmacology — inconclusive  working
    ├─ used  claim/34e216b7-f621-474f-ac54-6f9de55d12da  Claim in effects-overview — inconclusive  working
    ├─ used  claim/39946eb8-ef65-4ede-a362-3a2b5e9cad3b  Claim in pharmacology — inconclusive  working
    ├─ used  claim/ddf450b9-7e66-473f-bd96-a1cac0e76945  Claim in pharmacology — inconclusive  working
    ├─ used  claim/59e4ea50-9c9c-4253-a1fc-1a94a42189d9  Claim in history — inconclusive  working
    ├─ used  claim/1742a861-03c5-476c-ab7d-a026a4962d78  Claim in chemistry — inconclusive  working
    ├─ used  claim/c0bd00f0-b11b-46ce-9b60-e2e611168fe1  Claim in clinical-evidence — inconclusive  working
    ├─ used  claim/1f229d69-376b-49b4-a297-6538f0c0a9c8  Claim in history — inconclusive  working
    ├─ used  claim/c6b7a03b-bde2-4321-a29b-750f4ea59ba3  Claim in pharmacology — inconclusive  working
    ├─ used  claim/06d46933-e647-4de3-8700-f1e3358d603c  Claim in pharmacology — inconclusive  working
    ├─ used  claim/0e68fdb9-4353-43d3-a0ed-542848fe6e03  Claim in chemistry — inconclusive  working
    ├─ used  claim/72e09075-8c12-4233-95a5-2b0b9cdd4085  Claim in clinical-evidence — inconclusive  working
    ├─ used  claim/ba29891c-5d1c-42ec-bb56-c8aeeeaa60ee  Claim in safety — inconclusive  working
    ├─ used  claim/11ba1dfb-3ee3-4573-b838-38b40b5e0dd4  Claim in history — inconclusive  working
    ├─ used  claim/b9fd6e03-fd88-4dba-8efd-6929569947cb  Claim in safety — inconclusive  working
    ├─ used  claim/58bbe6c3-01df-4395-be33-295f4ed9d92b  Claim in history — inconclusive  working
    ├─ used  claim/2c910868-fb21-45c0-a565-95186162b0e9  Claim in neuroscience — inconclusive  working
    ├─ used  claim/bd47e3dc-970f-47de-bc75-a083c912b961  Claim in pharmacology — inconclusive  working
    ├─ used  claim/5339b019-fb4e-4c8e-be9c-5431897877e5  Claim in pharmacology — inconclusive  working
    ├─ used  claim/65405d32-fc32-443d-be9a-ba2c0c6bcd37  Claim in pharmacology — inconclusive  working
    ├─ used  claim/de9c92fd-3244-493f-a1a3-c2ae85601ea2  Claim in pharmacology — inconclusive  working
    ├─ used  claim/376eceb5-049b-4ac7-9944-159c785ac5df  Claim in neuroscience — inconclusive  working
    ├─ used  claim/0fa095f7-90e2-4c3a-816b-c0de7d636ac3  Claim in pharmacology — inconclusive  working
    ├─ used  claim/194fd803-513b-419f-acc9-8b786a1b700e  Claim in pharmacology — inconclusive  working
    ├─ used  claim/af5e5c71-0d4c-444a-8baa-2486e819e994  Claim in receptor-pharmacology — inconclusive  working
    ├─ used  claim/803d2437-323e-4286-854a-28bd534faafe  Claim in receptor-pharmacology — inconclusive  working
    ├─ used  claim/f81a87a6-3c14-4737-b291-de79c0010b45  Claim in pharmacology — inconclusive  working
    ├─ used  claim/0507024c-0dc1-4a97-8696-1c0e056e3a23  Claim in pharmacology — inconclusive  working
    ├─ used  claim/fe847fd9-e32c-4511-94a3-37a22ac1b378  Claim in receptor-pharmacology — inconclusive  working
    ├─ used  claim/a67382a3-da5a-42df-a8ba-c9f0924e5a54  Claim in receptor-pharmacology — inconclusive  working
    ├─ used  claim/838c1a0c-602a-4497-a071-d3ea427a4abf  Claim in pharmacology — inconclusive  working
    ├─ used  claim/f973c09d-5b12-420e-9c5e-f2a6b7a56a8e  Claim in receptor-pharmacology — inconclusive  working
    ├─ used  claim/ebf46d87-a7e1-4567-8586-4c8b1484e138  Claim in pharmacology — inconclusive  working
    ├─ used  claim/614beef1-51ae-4139-867c-d6ab81250e6d  Claim in receptor-pharmacology — inconclusive  working
    ├─ used  claim/66d893fa-58bc-4ce4-b6c8-4fd4cb506fee  Claim in pharmacology — inconclusive  working
    ├─ used  claim/b931d904-3580-42cb-a730-1f8dd613f13e  Claim in pharmacology — inconclusive  working
    ├─ used  claim/09793f05-551e-4f2f-830e-81cf7922e563  Claim in pharmacokinetic-detail — inconclusive  working
    ├─ used  claim/549a4d87-31bd-4716-b31d-45d29a38c621  Claim in pharmacology — inconclusive  working
    ├─ used  claim/eea57da0-6abe-4f02-94d1-6d570ec84c3c  Claim in pharmacology — inconclusive  working
    ├─ used  claim/d36cf360-f507-48e6-a623-1352cb1c2dfd  Claim in pharmacokinetic-detail — inconclusive  working
    ├─ used  claim/825022e5-256c-4e71-ab15-4fbb6e510faa  Claim in safety — inconclusive  working
    ├─ used  claim/9630b957-4dc9-4092-8d40-021388a611c3  Claim in safety — inconclusive  working
    ├─ used  claim/f7a56349-9a55-4944-863e-56cfa33542c8  Claim in safety — inconclusive  working
    ├─ used  claim/f853a073-3133-417d-9f3a-b85739a54474  Claim in safety — inconclusive  working
    ├─ used  claim/223483f1-33d6-425f-b712-2458453b9b62  Claim in safety — inconclusive  working
    ├─ used  claim/6886e540-f528-4d7b-b914-700eb7c2800b  Claim in safety — inconclusive  working
    ├─ used  claim/82f17c95-9f83-42ec-967b-bb75036f693c  Claim in safety — inconclusive  working
    ├─ used  claim/d6d66aeb-535e-44c9-ad4c-c54840459cdd  Claim in safety — inconclusive  working
    ├─ used  claim/122b968c-baa9-4a05-a7ec-75ab6f6c8ac7  Claim in pharmacology — inconclusive  working
    ├─ used  claim/a3a4c7ca-a825-44e9-a015-c9a6152f8781  Claim in pharmacology — inconclusive  working
    ├─ used  claim/ee990438-4661-40b7-a3c9-5aacddd11fdd  Claim in safety — inconclusive  working
    ├─ used  claim/e02e72af-583d-4961-bc3d-a3130cd52ffc  Claim in safety — inconclusive  working
    ├─ used  claim/0fed297a-4319-4e68-950e-10488d466b2e  Claim in comparative-pharmacology — inconclusive  working
    ├─ used  claim/9ab85bc9-1737-4cdc-a2bd-cc67ead60952  Claim in safety — inconclusive  working
    ├─ used  claim/48a8e351-c950-4976-b11a-5d95a80696cc  Claim in pharmacology — inconclusive  working
    ├─ used  claim/a8b23aa6-fc8c-4e6b-8b9a-01149dc3f4fe  Claim in pharmacology — inconclusive  working
    ├─ used  claim/edcecdf7-4992-4408-864d-06d389b5c55d  Claim in safety — inconclusive  working
    ├─ used  claim/bf3b8678-8ff2-4787-8692-271e0dd2d2c0  Claim in comparative-pharmacology — inconclusive  working
    ├─ used  claim/46029eb9-d746-4ee3-8b94-b29d25d119a8  Claim in neuroscience — inconclusive  working
    ├─ used  claim/4b94046b-8bc1-4ecf-9014-2d9cd79bcf5c  Claim in safety — inconclusive  working
    ├─ used  claim/00b151a0-933a-43a0-b549-e6cf38305acd  Claim in safety — inconclusive  working
    ├─ used  claim/60233415-c29a-463c-8d12-7fed713c3821  Claim in neuroscience — inconclusive  working
      ├─ derived_from  issue/notice@a978f9c7b775  Issued notice
      ├─ derived_from  issue/info_card@f310e2b88fa4  Issued info_card
      ├─ derived_from  issue/emergency@f85b2d2362c9  Issued emergency
      ├─ derived_from  issue/info_card@beb17ef0cb58  Issued info_card
      ├─ informed_by  section/safety.full@1
      ├─ informed_by  section/effects-overview.full@1
      ├─ informed_by  section/pharmacology.full@1
      ├─ informed_by  section/chemistry.full@1
      ├─ informed_by  section/pharmacokinetic-detail.full@1
      ├─ informed_by  section/comparative-pharmacology.full@1
      ├─ informed_by  section/history.full@1
      ├─ informed_by  section/clinical-evidence.full@1
      ├─ informed_by  section/neuroscience.full@1
      └─ informed_by  section/receptor-pharmacology.full@1
… closure truncated at 200 nodes

indented by distance from this node, not by parentage

1Provenance card

the boundary, as counts

Sources

5445 with DOI

28 strong · 22 moderate · 4 weak

Compilations

12026-04-27T23:28:09.792Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

62last ruled 2026-06-04

1 awaiting a ruling

Issued documents

42026-10-19T20:33:27.325Z

notice · info card · emergency

Searches

241 with no results

queries and counts on the build

Claims checked

2102 supported

2 supported · 208 not

Correspondence

0received

consent field ships in Phase 4

Edges

572

derivations recorded for this entity

Complete over 54 sources, 1 compilation, and 62 decisions.Not here: the private journal (never); 1 proposal awaiting a ruling (listed as pending only).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/oxycodone/archive

2Build

one panel per compilation run

generation run 2026-04-27

61 min completedmodel pipeline-v5plan not recordedrun/d439b974…

research

citationsRegistryrecordresearchOutputworking

draft

articleDraftworking

audit

articleAuditedworking

verify

verificationResultworking

simplify

articleSimplifiedworking

publish

runMetarecordrunSummaryrecord

Selection

results seen124
selected by the model47
consumed as sources54

Verification

claims checked210
supported2
partially supported0
not supported1
inconclusive207
  • record
  • seen / partial
  • working

The model's own caveats

  • taper_protocol_is_class_level
  • clonidine_adjunct_preclinical_only

1 further caveat recorded as free text — readable on the working page

Reproduce

inputs
54 source keys (listed under Sources)
plan
not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model
pipeline-v5
streams
none — agent transcripts are persisted from 2026-09 onward
24 searches — query, source, results, what was kept and why
24 searches for this run
#sourcequeryseenkeptrationale
1PubMedoxycodone pharmacokinetics bioavailability half-life metabolism CYP11—
2PubMed · absenceoxycodone history synthesis Martin Freund Edmund Speyer 19160——
3OpenAlexoxycodone pharmacology mechanism action opioid receptor103—
4OpenAlexoxycodone opioid epidemic prescription abuse overdose84—
5PubMedoxycodone overdose toxicity mortality respiratory depression32—
6PubChemoxycodone11—
7ClinicalTrials.govoxycodone pain treatment10——
8PubMedoxycodone dependence withdrawal physical psychological addiction abuse53—
9PubMedoxycodone pharmacology receptor binding mu opioid kappa opioid96—
10PubMedopioid metabolism review11—
11Britannica/Weboxycodone properties history legal status1——
12PubMedoxycodone opioid withdrawal syndrome treatment naloxone precipitated82—
13PubMedoxycodone bioavailability oral intranasal intravenous routes21—
14PubMedoxycodone CYP2D6 CYP3A4 metabolism oxymorphone noroxycodone105—
15Weboxycodone legal status scheduling UK Australia Canada controlled substance104—
16PubMedOxyContin reformulation abuse deterrent extended release oxycodone83—
17Weboxycodone synthesis history 1916 Freund Speyer thebaine Germany101—
18PubMedoxycodone drug interaction alcohol benzodiazepine CNS depressant52—
19PubMedoxycodone serotonin norepinephrine antidepressant interaction32—
20ChemicalBook/Weboxycodone physicochemical properties11—
21PubMedgabapentin pregabalin opioid respiratory depression overdose interaction risk22—
22OpenAlexoxycodone addiction opioid use disorder treatment outcomes52—
23Weboxycodone physicochemical DrugBank Ki values binding affinity10—Used available PubMed data instead (Olson 2019, Nielsen 2007) for receptor binding characterization
24StatPearls/NCBIoxycodone pharmacology11—
210 claims by section — every cited sentence, checked against its source
safety68 · 1 ok

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Gabapentinoids (pregabalin, gabapentin) co-prescription with opioids significantly increases the risk of opioid-related death in population-based studiessupported

    Population-based nested case-control study: co-prescription of gabapentin with opioids significantly increases risk of opioid-related death. journal.pmed.1002396

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

pharmacology44 · 0 ok

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

summary30 · 0 ok

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

pharmacokinetic-detail14 · 0 ok

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

history12 · 1 ok

  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • US opioid overdose deaths increased from approximately 4,000 in 1999 to over 47,000 in 2017, with prescription opioids — including oxycodone — implicated as the primary driver of the initial surge.supported

    Among 70,237 drug overdose deaths in 2017, 47,600 (67.8%) involved an opioid. Since 2013, driven largely by illicitly manufactured fentanyl, current wave marked by increases in synthetic opioid deaths. mmwr.mm675152e1

  • Claim in history — not_supportednot supportedworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

clinical-evidence10 · 0 ok

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

receptor-pharmacology10 · 0 ok

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

comparative-pharmacology8 · 0 ok

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

neuroscience8 · 0 ok

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

chemistry4 · 0 ok

  • Claim in chemistry — inconclusiveinconclusiveworking →

  • Claim in chemistry — inconclusiveinconclusiveworking →

  • Claim in chemistry — inconclusiveinconclusiveworking →

  • Claim in chemistry — inconclusiveinconclusiveworking →

effects-overview2 · 0 ok

  • Claim in effects-overview — inconclusiveinconclusiveworking →

  • Claim in effects-overview — inconclusiveinconclusiveworking →

3Sources

54 consumed · sorted by year · feeds = sections resting on it

Sources 1 to 30
yearsourcetierstatusfeeds
2026Mu Receptors (StatPearls/NCBI)Herman TF, Cascella M, Muzio MR, et al. · Pharmacology, Biochemistry and Behavior (via StatPearls)pmid:31855381moderateconsumed3 sections
2026Prescription of Controlled Substances: Benefits and RisksPreuss CV, Kalava A, King KC, et al. · Neurology internationaldoi:10.3390/neurolint13040059moderateconsumed1 section
2025Cannabidiol interactions with oxycodone analgesia in an operant orofacial cutaneous thermal pain assayBrice-Tutt AC, Murphy NP, Setlow B, et al. · Pharmacology, Biochemistry and Behaviordoi:10.1016/j.pbb.2025.173968strongconsumed1 section
2025Comprehensive Analysis of Strong Opioid Side Effects in Palliative Care Using the SIDER DatabaseHirai R, Kei M, Uesawa Y · Journal of Clinical Medicinedoi:10.3390/jcm14051410moderateconsumed1 section
2025Oxycodone/naloxone PR versus oxycodone PR in advanced cancer (ENhANCE trial)Wong AK, Grobler A, Mendis R, Philip J, Le B · Palliative Medicinedoi:10.1177/02692163251362563strongconsumed1 section
2024Altered Mental Status in an Octogenarian: Serotonin Syndrome from Venlafaxine and OxycodoneErdem S, Damlakhy A, Konja K, Bashar S · Cureusdoi:10.7759/cureus.57403weakconsumed1 section
2024Comparing withdrawal- and anxiety-like behaviors following oral and subcutaneous oxycodone administration in C57BL/6 miceDe Almeida SS, Drinkuth CR, Sartor GC · Behavioural Pharmacologydoi:10.1097/fbp.0000000000000780strongconsumedcited only
2024Do CYP2D6 genotypes affect oxycodone dose, pharmacokinetics, pain, and adverse effects in cancer?Wong AK, Vogrin S, Klepstad P, et al. · Pharmacogenomicsdoi:10.1080/14622416.2024.2430161moderateconsumed1 section
2024Oxycodone physicochemical properties (CAS 76-42-6)ChemicalBookurl:48f93c34f9e039f6weakconsumedcited only
2024Oxymorphone and Oxycodone Pharmacy Purchases in US Counties: Prelude to the Largest Rural HIV Outbreak in US HistoryDelcher C, Smith AL, Romanelli F, Gaskill L, Surratt HL · Pharmacoepidemiology and Drug Safetydoi:10.1002/pds.70066moderateconsumedcited only
2023Enzalutamide Reduces Oxycodone Exposure in Men with Prostate CancerDetert Oude Weme SEH, Hulskotte LMG, Vervenne WL, et al. · Clinical Pharmacokineticsdoi:10.1007/s40262-023-01255-1moderateconsumed1 section
2023Evaluating the effectiveness of reformulated extended-release oxycodone with abuse-deterrent properties on reducing non-oral abuseRodriguez RD, Dailey Govoni T, Rajagopal V, Green JL · Current Medical Research and Opiniondoi:10.1080/03007995.2023.2178080moderateconsumed1 section
2023Oxycodone pharmacology overview (StatPearls/NCBI Bookshelf)Multiple authorsurl:e866fccbb6332ecdweakconsumedcited only
2022A limited access oral oxycodone paradigm produces physical dependence and mesocorticolimbic region-dependent increases in DeltaFosB expression without preferenceIyer V, Woodward TJ, Pacheco R, Hohmann AG · Neuropharmacologydoi:10.1016/j.neuropharm.2021.108925strongconsumed3 sections
2022CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022Dowell D, Ragan K, Jones CM, et al. · MMWR Recommendations and Reportsdoi:10.15585/mmwr.rr7103a1moderateconsumedcited only
2022Characteristics of Prescription Opioid Analgesics in Pregnancy and Risk of Neonatal Opioid Withdrawal Syndrome in NewbornsEsposito DB, Huybrechts KF, Werler MM, et al. · JAMA Network Opendoi:10.1001/jamanetworkopen.2022.28588moderateconsumed1 section
2022Impact of genetic variation in CYP2C19, CYP2D6, and CYP3A4 on oxycodone and its metabolites in a large database of clinical urine drug testsZhu GD, Whitley P, LaRue L, et al. · The Pharmacogenomics Journaldoi:10.1038/s41397-021-00253-5moderateconsumed4 sections
2022Perinatal oxycodone exposure causes long-term sex-dependent changes in weight trajectory and sensory processing in adult miceMinakova E, Mikati MO, Madasu MK, et al. · Psychopharmacologydoi:10.1007/s00213-022-06257-8strongconsumed1 section
2021Drug-Drug Interaction Between Oxycodone and Diazepam by a Combined in Silico Pharmacokinetic and Pharmacodynamic Modeling ApproachJi B, Xue Y, Xu Y, Liu S, Gough AH, Xie XQ, Wang J · ACS Chemical Neurosciencedoi:10.1021/acschemneuro.0c00810strongconsumed1 section
2021Management of Opioid-Induced Constipation and Bowel DysfunctionDe Giorgio R, Zucco FM, Chiarioni G, et al. · Advances in Therapydoi:10.1007/s12325-021-01766-ymoderateconsumed2 sections
2021Minocycline attenuates oxycodone-induced positive subjective responses in non-dependent, recreational opioid usersMogali S, Askalsky P, Madera G, Jones JD, Comer SD · Pharmacology, Biochemistry and Behaviordoi:10.1016/j.pbb.2021.173241strongconsumed1 section
2021Validation and characterization of oxycodone physical dependence in C57BL/6J miceCarper M, Contreras KM, Walentiny DM, Beardsley PM, Damaj MI · European Journal of Pharmacologydoi:10.1016/j.ejphar.2021.174111strongconsumed1 section
2020Once-Daily Oxycodone Prolonged-Release Tablets Are Resistant to Alcohol-Induced Dose DumpingBurger N, Fraser D, Maritz MA, Faulkner J, Rey H · Clinical and Translational Sciencedoi:10.1111/cts.12737strongconsumed1 section
2020Physiologically based pharmacokinetic modelling of oxycodone drug-drug interactionsRytkönen J, Ranta VP, Kokki M, Kokki H, Hautajärvi H, Rinne V, Heikkinen AT · Biopharmaceutics & Drug Dispositiondoi:10.1002/bdd.2215strongconsumed2 sections
2020The impact of the abuse-deterrent reformulation of extended-release OxyContin on prescription pain reliever misuse and heroin initiationWolff C, Dowd WN, Ali MM, et al. · Addictive Behaviorsdoi:10.1016/j.addbeh.2019.106268moderateconsumedcited only
2019Comprehensive molecular pharmacology screening reveals potential new receptor interactions for clinically relevant opioidsOlson KM, Duron DI, Womer D, Fell R, Streicher JM · PLoS ONEdoi:10.1371/journal.pone.0217371strongconsumed3 sections
2019Dopamine D3R antagonist VK4-116 attenuates oxycodone self-administration and reinstatementYou ZB, Bi GH, Galaj E, Kumar V, Cao J, et al. · Neuropsychopharmacologydoi:10.1038/s41386-018-0284-5strongconsumed1 section
2019Updated Clinical Pharmacokinetics and Pharmacodynamics of OxycodoneKinnunen M, Piirainen P, Kokki H, Lammi P, Kokki M · Clinical Pharmacokineticsdoi:10.1007/s40262-018-00731-3strongconsumed5 sections
2018Drug and Opioid-Involved Overdose Deaths - United States, 2013-2017Scholl L, Seth P, Kariisa M, Wilson NO, Baldwin G · MMWR Morbidity and Mortality Weekly Reportdoi:10.15585/mmwr.mm675152e1moderateconsumed1 section
2018Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effectsBaldo BA · Archives of Toxicologydoi:10.1007/s00204-018-2244-6moderateconsumed1 section
Show all 55 sources — 25 more
Sources 31 to 55
yearsourcetierstatusfeeds
2017Characterization of [3H] oxymorphone binding sites in mouse brain: Quantitative autoradiography in opioid receptor knockout miceYoo JH, Borsodi A, Toth G, Benyhe S, Gaspar R, Matifas A, Kieffer BL, Metaxas A, Kitchen I, Bailey A · Neuroscience Lettersdoi:10.1016/j.neulet.2017.02.002strongconsumed1 section
2017Characterization of oxycodone in vitro metabolism by human cytochromes P450 and UDP-glucuronosyltransferasesRomand S, Spaggiari D, Marsousi N, et al. · Journal of Pharmaceutical and Biomedical Analysisdoi:10.1016/j.jpba.2016.09.024strongconsumed1 section
2017Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control studyGomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W · PLoS Medicinedoi:10.1371/journal.pmed.1002396moderateconsumed1 section
2017Risk to heroin users of polydrug use of pregabalin or gabapentinLyndon A, Audrey S, Wells C, Burnell ES, Ingle S, Hill R, Hickman M, Henderson G · Addictiondoi:10.1111/add.13843moderateconsumed1 section
2017Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuseRaleigh MD, Peterson SJ, Laudenbach M, et al. · PLoS ONEdoi:10.1371/journal.pone.0184876strongconsumed3 sections
2016CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016.Dowell D, Haegerich TM, Chou R · MMWR Recommendations and Reportsdoi:10.15585/mmwr.rr6501e1moderateconsumedcited only
2016Relationship between Nonmedical Prescription-Opioid Use and Heroin UseCompton WM, Jones CM, Baldwin G · New England Journal of Medicinedoi:10.1056/nejmra1508490strongconsumed1 section
2015Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolismMoody DE, Liu F, Fang WB · Journal of Analytical Toxicologydoi:10.1093/jat/bkv030strongconsumedcited only
2015Opioid Overdose Prevention Programs Providing Naloxone to Laypersons - United States, 2014Wheeler E, Jones TS, Gilbert MK, Davidson PJ · MMWR Morbidity and Mortality Weekly Reportpmid:26086633moderateconsumed1 section
2015Rates of opioid misuse, abuse, and addiction in chronic painVowles KE, McEntee ML, Siyahhan Julnes P, Frohe T, Ney JP · Paindoi:10.1097/01.j.pain.0000460357.01998.f1strongconsumed1 section
2015The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of AddictionKolodny A, Courtwright DT, Hwang CS, et al. · Annual Review of Public Healthdoi:10.1146/annurev-publhealth-031914-122957strongconsumed1 section
2015Trends in Opioid Analgesic Abuse and Mortality in the United StatesDart RC, Surratt HL, Cicero TJ, et al. · New England Journal of Medicinedoi:10.1056/nejmsa1406143moderateconsumed1 section
2013In vitro inhibition of methadone and oxycodone cytochrome P450-dependent metabolism: reversible inhibition by H2-receptor agonists and proton-pump inhibitorsMoody DE, Liu F, Fang WB · Journal of Analytical Toxicologydoi:10.1093/jat/bkt060strongconsumed1 section
2012Separate and combined psychopharmacological effects of alprazolam and oxycodone in healthy volunteersZacny JP, Paice JA, Coalson DW · Drug and Alcohol Dependencedoi:10.1016/j.drugalcdep.2012.01.023strongconsumed1 section
2010Does co-administration of paroxetine change oxycodone analgesiaLemberg KK, Heiskanen TE, Neuvonen M, et al. · Scandinavian Journal of Paindoi:10.1016/j.sjpain.2009.09.003strongconsumed3 sections
2010Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signalingMelief EJ, Miyatake M, Bruchas MR, Chavkin C · PNASdoi:10.1073/pnas.1000751107strongconsumed4 sections
2008Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert PanelPergolizzi J, Boger RH, Budd K, Dahan A, et al. · Pain Practicedoi:10.1111/j.1533-2500.2008.00204.xmoderateconsumed2 sections
2007Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic painNielsen CK, Ross FB, Lotfipour S, Saini KS, Edwards SR, Smith MT · Paindoi:10.1016/j.pain.2007.03.022strongconsumed3 sections
2007Oxycodone: a pharmacological and clinical reviewOrdóñez Gallego A, González Barón M, Espinosa Arranz E · Clinical & Translational Oncologypmid:17525040moderateconsumed7 sections
2004Discriminative stimulus, reinforcing, physical dependence, and antinociceptive effects of oxycodone in mice, rats, and rhesus monkeysBeardsley PM, Aceto MD, Cook CD, Bowman ER, Newman JL, Harris LS · Experimental and Clinical Psychopharmacologypmid:15301633strongconsumed2 sections
2003Oxycodone involvement in drug abuse deaths: a DAWN-based classification scheme applied to an oxycodone postmortem database containing over 1000 casesCone EJ, Fant RV, Rohay JM, et al. · Journal of Analytical Toxicologypmid:12669998moderateconsumed2 sections
2001Morphine and alternative opioids in cancer pain: the EAPC recommendationsHanks GW, De Conno F, Cherny NI, Hanna M, Kalso E · British Journal of Cancerdoi:10.1054/bjoc.2001.1680strongconsumed1 section
1997Pharmacokinetic comparison of intravenous and intranasal administration of oxycodoneTakala A, Kaasalainen V, Seppala T, Kalso E, Olkkola KT · Acta Anaesthesiologica Scandinavicapmid:9062618strongconsumedcited only
1916Oxycodone synthesis history (Freund & Speyer, 1916)Various historical sourcesurl:6424421adc42a45dweakconsumedcited only
—Searched PubMed for "oxycodone history synthesis Martin Freund Edmund Speyer 1916" — no resultsabsenceno results—

4Docket

one filing per activity — decisions, correspondence, reports

awaiting ruling — 1

  • dependence · taper2026-07-03
  1. 0012026-04-27revisionRevision 1

    Initial LLM generation (v5 pipeline, wiki)

    psx:substance/oxycodone/version/1
  2. 0022026-06-04proposal59 value proposals approved together

    one review action inferred from a shared reviewer and instant — the graph records one activity per proposal

    59 items in this filing

    • dose_tier · light
    • dose_tier · common
    • dose_tier · strong
    • dose_tier · heavy
    • timeline · oral · onset
    • timeline · oral · come_up
    • timeline · oral · peak
    • timeline · oral · plateau
    • timeline · oral · resolution
    • timeline · oral · afterglow
    • timeline · insufflated · onset
    • timeline · insufflated · come_up
    • timeline · insufflated · peak
    • timeline · insufflated · plateau
    • timeline · insufflated · resolution
    • timeline · insufflated · afterglow
    • timeline · intravenous · onset
    • timeline · intravenous · come_up
    • timeline · intravenous · peak
    • timeline · intravenous · plateau
    • timeline · intravenous · resolution
    • timeline · intravenous · afterglow
    • toxicity
    • dependence · full
    • withdrawal
    • tolerance
    • dosage · oral
    • dosage · insufflated
    • dosage · intravenous
    • duration · oral · onset
    • duration · oral · come_up
    • duration · oral · peak
    • duration · oral · offset
    • duration · oral · total
    • duration · oral · aftereffects
    • duration · insufflated · onset
    • duration · insufflated · come_up
    • duration · insufflated · peak
    • duration · insufflated · offset
    • duration · insufflated · total
    • duration · insufflated · aftereffects
    • duration · intravenous · onset
    • duration · intravenous · come_up
    • duration · intravenous · peak
    • duration · intravenous · offset
    • duration · intravenous · total
    • duration · intravenous · aftereffects
    • contraindication · respiratory
    • contraindication · respiratory
    • contraindication · other
    • contraindication · other
    • contraindication · psychiatric
    • contraindication · hepatic
    • contraindication · renal
    • contraindication · pregnancy_breastfeeding
    • contraindication · age
    • contraindication · metabolic
    • contraindication · psychiatric
    psx:substance/oxycodone/proposal/dose_tier/b47bdf5c-a1a8-4c4a-b083-70f7606b4bdc
  3. 0032026-06-04publicationPublication — backfill
    psx:substance/oxycodone/pub/a005318f-e6a8-46bc-bbca-9518d4baf5a3

5Issued documents

what the notice, info card and emergency page said, by hash

Issued documents
documentcontent hashissuedfrom versionsuperseded
info_cardbeb17ef0cb584efdb61eb917…2026-10-19 20:33Revision 1current
emergencyf85b2d2362c98030e2585598…2026-09-04 04:31Revision 1current
info_cardf310e2b88fa461921dbd62fe…2026-09-04 04:31Revision 1superseded2026-10-19
noticea978f9c7b775413055cd0636…2026-09-04 04:31Revision 1current